Literature DB >> 19200030

Genetics and function of the capsules of Burkholderia pseudomallei and their potential as therapeutic targets.

Shauna L Reckseidler-Zenteno1, Richard Moore, Donald E Woods.   

Abstract

Burkholderia pseudomallei is the causative agent of melioidosis, a fatal disease that is endemic to Southeast Asia and northern Australia. The clinical manifestations of melioidosis may range from an acute pneumonia or acute septicemia, to chronic and latent infections. B. pseudomallei is inherently resistant to a number of antibiotics, and even with aggressive antibiotic therapy, the mortality rate remains high, and the incidence of relapse is common. The resistance of this organism to a number of antibiotics has created a need for the development of other therapeutic strategies, including the identification of novel therapeutic targets. B. pseudomallei has been shown to produce a number of capsular polysaccharides, one of which has been shown to contribute to the virulence of the organism. The structures of these polysaccharides have been determined and the genes encoding for the biosynthesis of one of the capsular polysaccharides (CPS I) have been identified. Analysis of the genome sequence of this organism has revealed the presence of three other capsule gene clusters that may encode for the chemical structures previously identified. Since one of the capsules produced by B. pseudomallei has been shown to be important in virulence, the genes encoding for the proteins responsible for its biosynthesis may be considered as potential targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200030     DOI: 10.2174/138955709787316047

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  6 in total

1.  Present and future therapeutic strategies for melioidosis and glanders.

Authors:  D Mark Estes; Steven W Dow; Herbert P Schweizer; Alfredo G Torres
Journal:  Expert Rev Anti Infect Ther       Date:  2010-03       Impact factor: 5.091

2.  Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei.

Authors:  David P AuCoin; Dana E Reed; Nicole L Marlenee; Richard A Bowen; Peter Thorkildson; Barbara M Judy; Alfredo G Torres; Thomas R Kozel
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

3.  Delineating the importance of serum opsonins and the bacterial capsule in affecting the uptake and killing of Burkholderia pseudomallei by murine neutrophils and macrophages.

Authors:  Minal Mulye; Michael P Bechill; William Grose; Viviana P Ferreira; Eric R Lafontaine; R Mark Wooten
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

Review 4.  An Evolutionary Arms Race Between Burkholderia pseudomallei and Host Immune System: What Do We Know?

Authors:  Chalita Chomkatekaew; Phumrapee Boonklang; Apiwat Sangphukieo; Claire Chewapreecha
Journal:  Front Microbiol       Date:  2021-01-21       Impact factor: 5.640

5.  Comprehensive identification of virulence factors required for respiratory melioidosis using Tn-seq mutagenesis.

Authors:  Maria G Gutierrez; Deborah R Yoder-Himes; Jonathan M Warawa
Journal:  Front Cell Infect Microbiol       Date:  2015-11-04       Impact factor: 5.293

Review 6.  Mechanisms of Disease: Host-Pathogen Interactions between Burkholderia Species and Lung Epithelial Cells.

Authors:  Jonathan David; Rachel E Bell; Graeme C Clark
Journal:  Front Cell Infect Microbiol       Date:  2015-11-18       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.